Top Mutual Funds
Pharmaceuticals company Marksans Pharma announced Q4FY24 & FY24 results:
Q4FY24 Financial Highlights:
- Operating revenue was Rs 560.0 crore, up by 15.2% YoY driven by by volume gains, new launches, addition of new customers, and increase in our share with existing customers
- Gross profit was Rs 290.2 crore, up by 19.8% YoY with a Gross margin of 51.8%
- EBITDA was Rs 109.6 crore, grew by 0.1% with an EBITDA margin of 19.6%
- EPS was at Rs 1.73
FY24 Financial Highlights:
- Operating revenue was Rs 2,177.4 crore, up by 17.6% YoY
- US and North America business grew by 18.5% YoY
- UK and Europe grew by 22.9% YoY
- Gross profit was Rs 1,139.3 crore, up by 22.4% YoY with a Gross margin of 52.3%.
- EBITDA was Rs 458.6 crore, grew by 35.1% with an EBITDA margin of 21.1%
- EPS grew by 8.0% YoY to Rs 6.92
Mark Saldanha, Managing Director of the Company said “We are delighted to report a strong performance in FY24 in terms of both revenue and profitability. Our operating revenue for the year grew year-on-year by 18% and EBITDA increased by 35%, supported by new product launches, increase in market share, reduction in raw material prices and operating leverage. This year we have not only met but exceeded our revenue target of Rs 2,000 crore.
We remain confident on delivering sustained long-term value for our shareholders, as we position ourselves strongly in terms of infrastructure, product mix and long-term customer relationships.”
FAQ’s on Marksans Pharma Ltd Shares
